SynthesisFrontiers in endocrinology2025
Myonectin and metabolic health: a systematic review.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Exerkines in precision management of metabolic diseases.Chinese medical journal · 2026Review
- Recombinant myonectin ameliorates sepsis‑induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway.International journal of molecular medicine · 2026Article
- An overview of immunohistochemistry: Evidence and personal experience.The Journal of international medical research · 2026Review
- Circulating Myonectin and Oxytocin Levels in Pediatric Obesity: A Comparative Study.Children (Basel, Switzerland) · 2026Article
- Serum Albumin Level Predicts Systemic Arterial Stiffening Mediated Partially by Change in Lean Body Mass: A Retrospective Cohort Study in General Japanese Population.Vascular health and risk management · 2026Article
- Cisplatin-Induced Skeletal Muscle Atrophy: Biomolecular Mechanisms and the Protective Role of Exercise-Induced Myokines.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myonectin is a myokine with a potential role in metabolic health. This is a bibliometric and bioinformatics-complemented systematic review aimed to comprehensively analyze the structure, regulation and effects of myonectin on metabolic outcomes relevant to the pathophysiology of chronic metabolic diseases. Fifty-three studies involving cellular, animal, and human models were included. Findings indicate that myonectin is induced by aerobic exercise, nutrients, epinephrin, hypoxia and curcumin but is downregulated by obesity and muscle dysfunction. Evidence suggests that myonectin regulates lipid uptake and distribution across tissues, reduces inflammation and apoptosis and modulates mitochondrial function likely through the activation of AKT and AMP-activated protein kinase (AMPK)-mediated signaling pathways. While most results arising from human studies of good quality are in agreement with animal and cellular data, controversy remains and we discuss challenges and perspectives in the field. In conclusion, myonectin has a diverse role in regulating metabolic health, but a key contribution pertains to lipid regulation, which likely leads to a healthy expansion and distribution of adipose tissue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.